These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 18416582)

  • 41. Helicobacter pylori treatment in the era of increasing antibiotic resistance.
    Graham DY; Fischbach L
    Gut; 2010 Aug; 59(8):1143-53. PubMed ID: 20525969
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Prospective trial in Saudi Arabia comparing the 14-day standard triple therapy with the 10-day sequential therapy for treatment of Helicobacter pylori infection.
    Alsohaibani F; Al Ashgar H; Al Kahtani K; Kagevi I; Peedikayil M; Alfadda A; Khan M
    Saudi J Gastroenterol; 2015; 21(4):220-5. PubMed ID: 26228365
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Ten-day sequential therapy is more effective than proton pump inhibitor-based therapy in Korea: a prospective, randomized study.
    Oh HS; Lee DH; Seo JY; Cho YR; Kim N; Jeoung SH; Kim JW; Hwang JH; Park YS; Lee SH; Shin CM; Cho HJ; Jung HC; Song IS
    J Gastroenterol Hepatol; 2012 Mar; 27(3):504-9. PubMed ID: 21916989
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Comparison of the traditional triple and a new bismuth-containing quadruple therapy in the first-line eradication of
    Varga M; Drácz L; Kolbenheyer E; Varga F; Patai ÁV; Solymosi N; Patai Á
    Orv Hetil; 2019 Aug; 160(34):1340-1345. PubMed ID: 31423829
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Comparative study of Helicobacter pylori eradication rates of twice-versus four-times-daily amoxicillin administered with proton pump inhibitor and clarithromycin: a randomized study.
    Kim SY; Lee SW; Jung SW; Koo JS; Yim HJ; Park JJ; Chun HJ; Lee HS; Choi JH; Kim CD; Ryu HS
    Helicobacter; 2008 Aug; 13(4):282-7. PubMed ID: 18665938
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A Novel Potassium-Competitive Acid Blocker Improves the Efficacy of Clarithromycin-containing 7-day Triple Therapy against Helicobacter pylori.
    Noda H; Noguchi S; Yoshimine T; Goji S; Adachi K; Tamura Y; Izawa S; Ebi M; Yamamoto S; Ogasawara N; Funaki Y; Sasaki M; Kasugai K
    J Gastrointestin Liver Dis; 2016 Sep; 25(3):283-8. PubMed ID: 27689190
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Efficacy of moxifloxacin-based sequential and hybrid therapy for first-line Helicobacter pylori eradication.
    Hwang JJ; Lee DH; Yoon H; Shin CM; Park YS; Kim N
    World J Gastroenterol; 2015 Sep; 21(35):10234-41. PubMed ID: 26401089
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Concomitant, bismuth quadruple, and 14-day triple therapy in the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial.
    Liou JM; Fang YJ; Chen CC; Bair MJ; Chang CY; Lee YC; Chen MJ; Chen CC; Tseng CH; Hsu YC; Lee JY; Yang TH; Luo JC; Chang CC; Chen CY; Chen PY; Shun CT; Hsu WF; Hu WH; Chen YN; Sheu BS; Lin JT; Wu JY; El-Omar EM; Wu MS;
    Lancet; 2016 Nov; 388(10058):2355-2365. PubMed ID: 27769562
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Sequential therapy versus standard triple therapy for Helicobacter pylori eradication in children: any advantage in clarithromycin-resistant strains?
    Kutluk G; Tutar E; Bayrak A; Volkan B; Akyon Y; Celikel C; Ertem D
    Eur J Gastroenterol Hepatol; 2014 Nov; 26(11):1202-8. PubMed ID: 25171023
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Randomised controlled trial: susceptibility-guided therapy versus empiric bismuth quadruple therapy for first-line Helicobacter pylori treatment.
    Chen Q; Long X; Ji Y; Liang X; Li D; Gao H; Xu B; Liu M; Chen Y; Sun Y; Zhao Y; Xu G; Song Y; Yu L; Zhang W; Liu W; Graham DY; Lu H
    Aliment Pharmacol Ther; 2019 Jun; 49(11):1385-1394. PubMed ID: 31020673
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Impact of furazolidone-based quadruple therapy for eradication of Helicobacter pylori after previous treatment failures.
    Treiber G; Ammon S; Malfertheiner P; Klotz U
    Helicobacter; 2002 Aug; 7(4):225-31. PubMed ID: 12165029
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Empirical levofloxacin-containing versus clarithromycin-containing sequential therapy for Helicobacter pylori eradication: a randomised trial.
    Romano M; Cuomo A; Gravina AG; Miranda A; Iovene MR; Tiso A; Sica M; Rocco A; Salerno R; Marmo R; Federico A; Nardone G
    Gut; 2010 Nov; 59(11):1465-70. PubMed ID: 20947881
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Seven-day triple therapy is a better choice for Helicobacter pylori eradication in regions with low antibiotic resistance.
    Tong YF; Lv J; Ying LY; Xu F; Qin B; Chen MT; Meng F; Tu MY; Yang NM; Li YM; Zhang JZ
    World J Gastroenterol; 2015 Dec; 21(46):13073-9. PubMed ID: 26672777
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Sequential therapy for 10 days versus triple therapy for 14 days in the eradication of
    Liou JM; Chen CC; Chang CY; Chen MJ; Chen CC; Fang YJ; Lee JY; Yang TH; Luo JC; Wu JY; Liou TC; Chang WH; Hsu YC; Tseng CH; Chang CC; Bair MJ; Liu TY; Hsieh CF; Tsao FY; Shun CT; Lin JT; Lee YC; Wu MS;
    Gut; 2016 Nov; 65(11):1784-1792. PubMed ID: 26338825
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Ten-day sequential treatment for Helicobacter pylori eradication in clinical practice.
    Sánchez-Delgado J; Calvet X; Bujanda L; Gisbert JP; Titó L; Castro M
    Am J Gastroenterol; 2008 Sep; 103(9):2220-3. PubMed ID: 18564109
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A comparison between 15-day sequential, 10-day sequential and proton pump inhibitor-based triple therapy for Helicobacter pylori infection in Korea.
    Lee JW; Kim N; Kim JM; Nam RH; Kim JY; Lee JY; Lee DH; Jung HC
    Scand J Gastroenterol; 2014 Aug; 49(8):917-24. PubMed ID: 24988873
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Sequential treatment for Helicobacter pylori eradication in duodenal ulcer patients: improving the cost of pharmacotherapy.
    Hassan C; De Francesco V; Zullo A; Scaccianoce G; Piglionica D; Ierardi E; Panella C; Morini S
    Aliment Pharmacol Ther; 2003 Sep; 18(6):641-6. PubMed ID: 12969091
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Randomized clinical trial comparing ten day concomitant and sequential therapies for Helicobacter pylori eradication in a high clarithromycin resistance area.
    Georgopoulos SD; Xirouchakis E; Martinez-Gonzales B; Zampeli E; Grivas E; Spiliadi C; Sotiropoulou M; Petraki K; Zografos K; Laoudi F; Sgouras D; Mentis A; Kasapidis P; Michopoulos S
    Eur J Intern Med; 2016 Jul; 32():84-90. PubMed ID: 27134145
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Yields of dual therapy containing high-dose proton pump inhibitor in eradication of H. pylori positive dyspeptic patients.
    Ince AT; Tozlu M; Baysal B; Şentürk H; Arıcı S; Özden A
    Hepatogastroenterology; 2014; 61(133):1454-8. PubMed ID: 25436324
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Systematic review with meta-analysis: Vonoprazan, a potent acid blocker, is superior to proton-pump inhibitors for eradication of clarithromycin-resistant strains of Helicobacter pylori.
    Li M; Oshima T; Horikawa T; Tozawa K; Tomita T; Fukui H; Watari J; Miwa H
    Helicobacter; 2018 Aug; 23(4):e12495. PubMed ID: 29873436
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.